Ironwood Pharmaceuticals, Inc.
IRWD
$3.25
-$0.12-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.71M | 122.06M | 85.24M | 41.14M | 90.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.71M | 122.06M | 85.24M | 41.14M | 90.55M |
| Cost of Revenue | 21.86M | 22.47M | 23.37M | 27.43M | 25.39M |
| Gross Profit | 25.85M | 99.59M | 61.87M | 13.71M | 65.15M |
| SG&A Expenses | 19.29M | 21.91M | 16.80M | 24.26M | 33.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.16M | 44.38M | 40.17M | 51.69M | 58.98M |
| Operating Income | 6.55M | 77.68M | 45.07M | -10.55M | 31.56M |
| Income Before Tax | 455.00K | 68.02M | 37.82M | -36.27M | 24.00M |
| Income Tax Expenses | 2.73M | 27.94M | 14.22M | 1.11M | 21.74M |
| Earnings from Continuing Operations | -2.28M | 40.08M | 23.60M | -37.39M | 2.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.28M | 40.08M | 23.60M | -37.39M | 2.26M |
| EBIT | 6.55M | 77.68M | 45.07M | -10.55M | 31.56M |
| EBITDA | 7.01M | 78.16M | 45.54M | -10.07M | 32.05M |
| EPS Basic | -0.01 | 0.25 | 0.15 | -0.23 | 0.01 |
| Normalized Basic EPS | 0.00 | 0.27 | 0.15 | -0.07 | 0.09 |
| EPS Diluted | -0.02 | 0.23 | 0.14 | -0.23 | 0.01 |
| Normalized Diluted EPS | 0.00 | 0.25 | 0.13 | -0.07 | 0.09 |
| Average Basic Shares Outstanding | 162.44M | 162.22M | 161.72M | 160.97M | 159.90M |
| Average Diluted Shares Outstanding | 162.44M | 177.76M | 176.84M | 160.97M | 160.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |